LON:SLN Silence Therapeutics - SLN Share Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Silence Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Add Compare Share Share Today's Range N/A50-Day Range 535▼ 53552-Week Range N/AVolume913,528 shsAverage Volume80,100 shsMarket Capitalization£480.35 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlines About Silence Therapeutics (LON:SLN) StockSilence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase Ib clinical trials for the treatment of myelodysplastic syndrome; and SLN500 for the treatment of complement-mediated diseases. It has a collaboration agreements with AstraZeneca to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.Read More Receive SLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SLN Stock News HeadlinesMarch 19, 2023 | americanbankingnews.comSilence Therapeutics (LON:SLN) Shares Pass Below Two Hundred Day Moving Average of $535.00February 8, 2023 | finance.yahoo.comSilence Therapeutics to Present at SVB Securities Global Biopharma ConferenceMarch 24, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.February 6, 2023 | wsj.comSilence Therapeutics Appoints J.P. Gabriel as Chief Technical Operations OfficerJanuary 12, 2023 | finance.yahoo.comSilence Therapeutics Provides SLN360 and SLN124 Clinical Program UpdatesNovember 10, 2022 | finanznachrichten.deSilence Therapeutics plc: Silence Therapeutics Reports Third Quarter 2022 ResultsSeptember 29, 2022 | finance.yahoo.comSilence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with ThalassemiaSeptember 27, 2022 | finance.yahoo.comSilence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines ConferenceMarch 24, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. August 13, 2022 | finanznachrichten.deSilence Therapeutics plc: Silence Therapeutics Announces Pricing of Underwritten OfferingJuly 15, 2022 | wsj.comSilence Therapeutics PLC ADRJune 17, 2022 | benzinga.comSilence Therapeutics (NASDAQ:SLN), Short Interest ReportMay 18, 2022 | finance.yahoo.comSilence Therapeutics to Participate in Fireside Chat at H.C. Wainwright Global Investment ConferenceMarch 23, 2022 | seekingalpha.comSilence Therapeutics to get $3M from Mallinckrodt as trial application for SLN501 filedMarch 23, 2022 | finance.yahoo.comSilence Therapeutics and Mallinckrodt Announce Submission of Clinical Trial Application for SLN501March 17, 2022 | finanznachrichten.deSilence Therapeutics plc: Silence Therapeutics Reports Fourth Quarter and Full Year 2021 ResultsMarch 17, 2022 | benzinga.comSilence Therapeutics Reports FY21 Sales £12.4M Up From £5.5M YoYMarch 17, 2022 | finance.yahoo.comSilence Therapeutics Reports Fourth Quarter and Full Year 2021 ResultsFebruary 26, 2022 | seekingalpha.comSilence Therapeutics granted Orphan Drug status for rare blood disorder candidateFebruary 9, 2022 | finance.yahoo.comSilence Therapeutics Posts First Human Data For Cardiovascular CandidateJanuary 18, 2022 | finance.yahoo.comSilence Therapeutics’ Head of Molecular Design Dr. Marie Wikström Lindholm Appointed to Oligonucleotide Therapeutics Society Board of DirectorsJanuary 5, 2022 | finance.yahoo.comSilence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Virtual ConferenceDecember 16, 2021 | finanznachrichten.deSilence Therapeutics plc: Silence Therapeutics Begins Exclusive Nasdaq TradingNovember 30, 2021 | finance.yahoo.comSilence Therapeutics Begins Exclusive Nasdaq TradingNovember 27, 2021 | markets.businessinsider.comSilence Therapeutics : Update on AIM DelistingNovember 16, 2021 | proactiveinvestors.comSilence Therapeutics: Data and clinical progress will be the catalysts, says London brokerNovember 11, 2021 | finance.yahoo.comSilence Therapeutics to Present at Jefferies London Healthcare ConferenceSee More Headlines Receive SLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SLN Company Calendar Last Earnings9/14/2020Today3/24/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:SLN CUSIPN/A CIKN/A Webwww.silence-therapeutics.com Phone+44-20-34576900FaxN/AEmployees74Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.80 Current Ratio4.52 Quick Ratio4.36 Sales & Book Value Annual Sales£11.35 million Price / Sales42.34 Cash FlowGBX 84.41 per share Price / Cash Flow6.34 Book ValueGBX 18.20 per share Price / Book29.40Miscellaneous Outstanding Shares89,785,000Free FloatN/AMarket Cap£480.35 million OptionableNot Optionable BetaN/A Key ExecutivesMr. Mark Andrew Rothera (Age 58)Pres, CEO & Exec. Director Comp: $521.23kDr. Giles V. Campion M.D. (Age 67)Exec. VP, Head of R&D, Chief Medical Officer and Exec. Director Comp: $436.2kMr. Craig A. Tooman M.B.A. (Age 55)MBA, Chief Financial Officer Ms. Gem Gokmen HopkinsHead of IR & Corp. CommunicationsDr. Barbara A. Ruskin (Age 61)Sr. VP, Gen. Counsel & Chief Patent Officer Ms. Linnea ElringtonVP & Head of HRDr. John StraffordVP & Head of Bus. Devel.Mr. Jørgen WittendorffSr. VP & Head of ManufacturingDr. Marie Wikstrom Lindholm Ph.D.Sr. VP & Head of Molecular DesignMore ExecutivesKey CompetitorsErgomedLON:ERGOOxford BiomedicaLON:OXBPureTech HealthLON:PRTCHorizon Discovery Group plc (HZD.L)LON:HZDVerona Pharma plc (VRP.L)LON:VRPView All Competitors SLN Stock - Frequently Asked Questions How have SLN shares performed in 2023? Silence Therapeutics' stock was trading at GBX 535 at the beginning of the year. Since then, SLN shares have increased by 0.0% and is now trading at GBX 535. View the best growth stocks for 2023 here. How were Silence Therapeutics' earnings last quarter? Silence Therapeutics plc (LON:SLN) released its quarterly earnings data on Monday, September, 14th. The company reported ($13.70) earnings per share for the quarter, topping analysts' consensus estimates of ($21.70) by $8.00. What other stocks do shareholders of Silence Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Silence Therapeutics investors own include Arch Therapeutics (ARTH), QuickLogic (QUIK), Asiamet Resources (ARS), ArcBest (ARCB), American Renal Associates (ARA), Apergy (APY), Anchiano Therapeutics (ANCN), Aileron Therapeutics (ALRN), Alkermes (ALKS) and Alfa Financial Software (ALFA). What is Silence Therapeutics' stock symbol? Silence Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "SLN." How do I buy shares of Silence Therapeutics? Shares of SLN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Silence Therapeutics' stock price today? One share of SLN stock can currently be purchased for approximately GBX 535. How much money does Silence Therapeutics make? Silence Therapeutics (LON:SLN) has a market capitalization of £480.35 million and generates £11.35 million in revenue each year. How can I contact Silence Therapeutics? Silence Therapeutics' mailing address is 72 Hammersmith Road, LONDON, W14 8TH, United Kingdom. The official website for the company is www.silence-therapeutics.com. The company can be reached via phone at +44-20-34576900. This page (LON:SLN) was last updated on 3/24/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.